With its growth characteristic and chemoresistance, glioblastoma is the most deadly brain tumor. Twenty-five core genes that influence the chemosensitivity of glioblastoma were screened in our previous experiments, and Id2, the inhibitor of DNA binding 2, an oncogene encoding a helix–loop–helix protein, was identified. The elevated expression levels of Id2 have been reported in several malignancies. The aim of this study is to investigate the effects of Id2 expression on the chemosensitivity of glioma cells. In this study, Id2 expression was investigated in a malignant glioma cell line. Then, we silenced the expression of Id2 with the highly specific posttranscriptional suppression of RNA interference (RNAi) in U87 cells. The changes in response to antitumor agents Me-CCNU, VM26, and TMZ were evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Apoptosis was measured using an annexin V–fluorescein isothiocyanate (FITC) apoptosis detection kit. The relationship between Id2 expression and caspase 3 was tested by RT-PCR and Western blot. This study demonstrated that Id2 was significantly upregulated in glioma tissues, and Id2 correlated well with the advancement of glioma grade and a worse prognosis in response to temozolomide treatment. The RNAi-mediated decrease of Id2 expression enhanced chemosensitivity to Me-CCNU, VM26, and TMZ in the U87 cell line. We further discovered that silencing of Id2 expression could promote apoptosis of glioblastoma cells, which could be attributed to the fact that Id2 affects tumor cell chemosensitivity. Downregulation of the Id2 gene by RNAi could increase the chemosensitivity of glioblastoma cells. Id2 could be a good molecular target for glioblastoma gene therapy.
Inhibitor of DNA binding 2, dominant negative helix–loop–helix protein
Small interfering RNA
Reverse transcription-polymerase chain reaction
This is a preview of subscription content, log in to check access.
This work was supported by the National Natural Science Foundation of China (No. 81302187 and No. 30930094) and medical technological innovation funding of Nanjing Military Region in 2014 (No. ZD15).
Conflict of interest
Zhao J, He H, Zhou K, Ren Y, Shi Z, Wu Z, et al. Neuronal transcription factors induce conversion of human glioma cells to neurons and inhibit tumorigenesis. PLoS One. 2012;7:e41506.CrossRefPubMedPubMedCentralGoogle Scholar
Tao BB, He H, Shi XH, Wang CL, Li WQ, Li B, et al. Upregulation of USP2a and FASN in gliomas correlates strongly with glioma grade. J Clin Neurosci. 2013;20:717–20.CrossRefPubMedGoogle Scholar
Trabosh VA, Divito KA, D Aguda B, Simbulan-Rosenthal CM, Rosenthal DS. Sequestration of E12/E47 and suppression of p27KIP1 play a role in Id2-induced proliferation and tumorigenesis. Carcinogenesis. 2009;30:1252–9.CrossRefPubMedPubMedCentralGoogle Scholar
Lasorella A, Rothschild G, Yokota Y, Russell RG, Iavarone A. Id2 mediates tumor initiation, proliferation, and angiogenesis in Rb mutant mice. Mol Cell Biol. 2005;25:3563–74.CrossRefPubMedPubMedCentralGoogle Scholar
Meng Y, Gu C, Wu Z, Zhao Y, Si Y, Fu X, et al. Id2 promotes the invasive growth of MCF-7 and SKOV-3 cells by a novel mechanism independent of dimerization to basic helix-loop-helix factors. BMC Cancer. 2009;9:75.CrossRefPubMedPubMedCentralGoogle Scholar
Coppe JP, Itahana Y, Moore DH, Bennington JL, Desprez PY. Id1 and Id2 proteins as molecular markers for human prostate cancer progression. Clin Cancer Res. 2004;10:2044–51.CrossRefPubMedGoogle Scholar
Han W, Wu Z, Zhao Y, Meng Y, Si Y, Yang J, et al. FHL2 interacts with and acts as a functional repressor of Id2 in human neuroblastoma cells. Nucleic Acids Res. 2009;37:3996–4009.CrossRefPubMedPubMedCentralGoogle Scholar
Stallone G, Infante B, Pontrelli P, Ranieri E, Loverre A, Schena A, et al. ID2-VEGF-related pathways in the pathogenesis of Kaposi’s sarcoma: a link disrupted by rapamycin. Am J Transplant. 2009;9:558–66.CrossRefPubMedGoogle Scholar
Spiegel BM, Esrailian E, Laine L, Chamberlain MC. Clinical impact of adjuvant chemotherapy in glioblastoma multiforme: a meta-analysis. CNS Drugs. 2007;21:775–87.CrossRefPubMedGoogle Scholar